We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Ensovibep

News List

Novartis and Molecular Partners report positive topline data from Phase 2 study for ensovibep (MP0420), a DARPin antiviral therapeutic for COVID-19 WorldPharmaNews
January 13, 2022
Novartis and Molecular Partners announced that Part A of the EMPATHY clinical trial(1) that compared single intravenous doses of ensovibep, a DARPin antiviral therapeutic candidate vs. placebo to treat COVID-19...
Novartis and Molecular Partners report positive topline data from phase-II study for Ensovibep ExpressPharma
January 11, 2022
The secondary endpoint of hospitalisation and/or ER visits related to COVID-19, or death showed an overall 78 per cent reduction in risk of events across Ensovibep arms compared to placebo.
Novartis and Molecular Partners commence Covid-19 treatment trial pharmaceutical-technology
May 31, 2021
Novartis and Molecular Partners have commenced Phase II/III EMPATHY clinical trial of a new DARPin therapeutic candidate, ensovibep (MP0420), to treat Covid-19.